Jerusalem Pharmaceuticals Co. Ltd. announced audited consolidated earnings results for the year ended December 31, 2017. For the year, the company reported Sales of USD 35,154,346 as compared to USD 28,601,050 a year ago. Net Income before tax was USD 6,265,727 as compared to USD 3,230,008 a year ago. Net Income after tax was USD 6,163,670 as compared to USD 3,050,959 a year ago. Diluted and basic loss per share were USD 0.341 as compared to USD 0.176 a year ago. Net Cash Flow from Operating Activities was USD 4,748,463 as compared to USD 2,483,558 a year ago. Purchase of Property, Plant and Equipment was USD 1,702,181 as compared to USD 699,065 a year ago. Purchase of intangible assets was USD 325,923 as compared to USD 207,657 a year ago.